Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations

被引：3
|
作者：
Yoon, Shinkyo [1 ]
Lee, Dae Ho [1 ]
Kim, Sang-We [1 ]
机构：
[1] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2017年 / 5卷 / 01期
关键词：
RANDOMIZED PHASE-II; EGFR MUTATIONS; OPEN-LABEL; ERLOTINIB; TRIAL; COMBINATION; NSCLC; ADENOCARCINOMA; CHEMOTHERAPY; BEVACIZUMAB;
D O I：
10.21037/atm.2016.12.64
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
    Kim, Young Hak
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 692 - +
  • [2] Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
    Cheng, Ying
    Murakami, Haruyasu
    Yang, Pan-Chyr
    He, Jianxing
    Nakagawa, Kazuhiko
    Kang, Jin Hyoung
    Kim, Joo-Hang
    Wang, Xin
    Enatsu, Sotaro
    Puri, Tarun
    Orlando, Mauro
    Yang, James Chih-Hsin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) : 3258 - +
  • [3] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    H Asahina
    K Yamazaki
    I Kinoshita
    N Sukoh
    M Harada
    H Yokouchi
    T Ishida
    S Ogura
    T Kojima
    Y Okamoto
    Y Fujita
    H Dosaka–Akita
    H Isobe
    M Nishimura
    [J]. British Journal of Cancer, 2006, 95 : 998 - 1004
  • [4] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    Asahina, H.
    Yamazaki, K.
    Kinoshita, I.
    Sukoh, N.
    Harada, M.
    Yokouchi, H.
    Ishida, T.
    Ogura, S.
    Kojima, T.
    Okamoto, Y.
    Fujita, Y.
    Dosaka-Akita, H.
    Isobe, H.
    Nishimura, M.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (08) : 998 - 1004
  • [5] FIRST LINE GEFITINIB IN YOUNGER PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
    Elhidsi, Mia
    Hudoyo, Ahmad
    Andarini, Sita
    [J]. RESPIROLOGY, 2015, 20 : 100 - 100
  • [6] First-line cisplatin plus pemetrexed therapy for selected patients with advanced nonsquamous non-small cell lung cancer.
    Nakashima, Kazuhisa
    Murakami, Haruyasu
    Imai, Hisao
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations
    Decoster, Lore
    Giron, Philippe
    Mignon, Sacha
    De Greve, Jacques
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S134 - S137
  • [8] EFFECTIVENESS OF FIRST-LINE PEMETREXED PLUS PLATINUM FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Brandao, M. D. R. A.
    Luis, M. S.
    Amaral, N. C.
    Cassiano Neves, M.
    Camacho, C.
    Rodrigues, A. C.
    Pousa, I.
    Oliveira, J.
    Azevedo, I.
    [J]. ANNALS OF ONCOLOGY, 2015, 26
  • [9] Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Wielage, Ron
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Lawson, Anthony
    Schwartzberg, Lee
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1263 - 1272
  • [10] Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
    Gridelli, C.
    De Marinis, F.
    Di Maio, M.
    Cortinovis, D.
    Cappuzzo, F.
    Mok, T.
    [J]. LUNG CANCER, 2011, 71 (03) : 249 - 257
12345